Sarsia Seed AS
Sarsia Seed AS is a Norwegian seed capital fund based in Bergen, specializing in early-phase technology investments. The fund focuses on the energy/cleantech and biotechnology/life science sectors, aiming to support innovative companies in these fields. With a total capital of approximately 333.5 million NOK, Sarsia Seed AS is managed by Sarsia Seed Management AS, which provides strategic advice to the fund's board on investment decisions. The fund is structured for a duration of 12 years, with the possibility of an extension. The management team boasts a diverse skill set, combining expertise in operations, business development, specialized technology, applied research, and entrepreneurship. This collective experience enhances their ability to effectively evaluate and monitor investments, leveraging a broad national and international network of industrial partners and co-investors.
Heimdall Power AS develops a sensor platform that provides situational awareness along transmission lines and distribution feeders. The device is known under the name Neuron. The platform features include line monitoring, real time feeder visualization, fault detection and analysis, dynamic line rating, and heimdall quality. The company was incorporated in 2015 and is based in Bergen, Norway.
BrainImage is the provider of SonoClear® - an acoustic coupling fluid for enhanced ultrasound imaging. This technology removes surgically induced image artefacts providing basis for enhanced clinical decision support.
BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
APIM Therapeutics AS is a biotechnology company based in Trondheim, Norway, founded in 2009. The company specializes in developing combinatorial therapies for cancer treatment, focusing on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA). PCNA plays a crucial role in DNA repair and cellular responses to DNA damage and stress, making it a significant target for cancer therapies. One of the company's key compounds, ATX-101, has demonstrated proof-of-concept in various preclinical in vitro and in vivo cancer models. The foundation of APIM Therapeutics is rooted in original research by Professor Marit Otterlei and her team at the Department of Cancer Research and Molecular Medicine at NTNU.
BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
APIM Therapeutics AS is a biotechnology company based in Trondheim, Norway, founded in 2009. The company specializes in developing combinatorial therapies for cancer treatment, focusing on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA). PCNA plays a crucial role in DNA repair and cellular responses to DNA damage and stress, making it a significant target for cancer therapies. One of the company's key compounds, ATX-101, has demonstrated proof-of-concept in various preclinical in vitro and in vivo cancer models. The foundation of APIM Therapeutics is rooted in original research by Professor Marit Otterlei and her team at the Department of Cancer Research and Molecular Medicine at NTNU.
BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
Avexxin's therapeutic approach is built on more than a decade of research into the biological mechanisms involved in inflammatory diseases at the Norwegian University of Science and Technology. Avexxin's goal is to create a therapeutic company based on the discovery and development of novel therapeutics that address the fundamental mechanisms involved in inflammatory diseases.
WindSim AS provides software for the simulation of wind resources in complex terrain. It offers WindSim, a simulator for optimizing the energy production from wind turbines in Europe, Asia, Australia, and North America. It also offers consulting and training related to the use of WindSim. The company provides its products through distributors in China, France, Germany, Italy, Spain, and Taiwan.
WindSim AS was formerly known as VECTOR AS and changed its name to WindSim AS in December 2005. The company is based in Tonsberg, Norway.